bioAffinity Technologies, Inc. BIAF 深 滬
等待開盤 03-26 09:30:00 美东时间
3.97
+0.010
+0.25%
華盛通- 最 高4.9699
- 今 開4.595
- 成交量 1315.00万股
- 最 低 3.795
- 昨 收 3.96
- 總市值 1785.98万
- 52周最高 23.10
- 市盈率 靜 --
- 換手率 292.31%
- 52周最低 0.693
- 委 比 -83.24%
- 總股本 449.87万
- 歷史最高 466.50
- 量 比 0.69
- 振 幅 29.67%
- 歷史最低 0.693
- 每 手 1
- 風險率 5.02%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股夜盘 | Paranovus Entertainment Technology Ltd. - Class A Ordinary Shares涨76.68%，Epsium Enterprise涨20.73%
Paranovus Entertainment Technology Ltd. - Class A Ordinary Shares涨76.68%；Epsium Enterprise涨20.73%；网络齿轮通信涨14.73%
03-24 09:03
美股夜盘 | Paranovus Entertainment Technology Ltd. - Class A Ordinary Shares涨52.99%，Thryv Holdings, Inc.涨20.88%
Ambitions Enterprise Management涨-16.07%；Powell Max Limited Class A涨-12.06%；bioAffinity Technologies, Inc.涨-11.42%
03-24 08:11
What's Going On With bioAffinity Stock Thursday?
BioAffinity stock dips after huge gains. Its CyPath Lung test shows strong results in diagnosing nodules without invasive procedures.
03-19 21:13
美股夜盘 | Health In Tech, Inc. Class A涨50.00%，ZenaTech, Inc.涨19.30%
Health In Tech, Inc. Class A涨50.00%；ZenaTech, Inc.涨19.30%；金山云涨15.24%
03-18 15:03
美股夜盘 | Health In Tech, Inc. Class A涨52.94%，ZenaTech, Inc.涨18.42%
Health In Tech, Inc. Class A涨52.94%；ZenaTech, Inc.涨18.42%；万达生物制药涨10.81%
03-18 13:02
美股夜盘 | Health In Tech, Inc. Class A涨50.00%，Energy Vault涨14.29%
Health In Tech, Inc. Class A涨50.00%；Energy Vault涨14.29%；万达生物制药涨10.58%
03-18 10:02
美股夜盘 | Health In Tech, Inc. Class A涨52.35%，Diginex Ltd.涨13.38%
Health In Tech, Inc. Class A涨52.35%；Diginex Ltd.涨13.38%；万达生物制药涨11.28%
03-18 09:02
美股夜盘 | Health In Tech, Inc. Class A涨27.06%，SHF Holdings Inc Class A涨11.49%
有信科技涨-19.52%；美物科技涨-17.76%；优品车涨-16.52%
03-18 08:13
Why Is bioAffinity Technologies Stock Surging Tuesday?
bioAffinity Technologies (BIAF) stock surges Tuesday after a new case study confirms CyPath Lung's role in noninvasive cancer diagnostics. Details here.
03-17 22:32
bioAffinity Technologies Releases New Clinical Case Study Highlighting Benefit Of Adding CyPath Lung To Diagnostic Pathway For High-Risk Patient With Multiple Pulmonary Nodules
CyPath® Lung improves diagnostic clarity in patients with multiple lung nodulesIn this case study, CyPath® Lung "Unlikely Malignancy" result supported physician's decision to wait before ordering an invasive
03-17 19:51
